GF25
Anti-VEGF (Ab-3) Mouse mAb (14-124)
Synonym(s):
Anti-Vascular Permeability Factor, Anti-VPF, Anti-Vascular Endothelial Growth Factor
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
antibody form
purified antibody
clone
14-124, monoclonal
form
liquid
contains
≤0.1% sodium azide as preservative
species reactivity
human
isotype
IgG1
General description
Purified mouse monoclonal antibody generated by immunizing Balb/c mice with the specified immunogen and fusing splenocytes with mouse SP2/0 cells. Recognizes the ~31-50 kDa VEGF121, VEGF165, VEGF189, and VEGF206 proteins.
Recognizes the ~31-50 kDa VEGF121, VEGF165, VEGF189, and VEGF206 proteins.
This Anti-VEGF (Ab-3) Mouse mAb (14-124) is validated for use in Immunoblotting, Paraffin Sections for the detection of VEGF (Ab-3).
Vascular endothelial growth factor (VEGF), also known as vascular permeability factor (VPF), is a secreted heparin binding cytokine expressed in tumor and animal cells. VEGF has been implicated in the control of angiogenesis due to its selective mitogenic stimulation of vascular endothelial cells and enhancement of vascular permeability. Other effects of VEGF on vascular endothelial cells include; increasing intracellular calcium, stimulating inositol triphosphate formation, induction of von Willebrand factor release, and stimulating tissue factor expression. VEGF is a ~46 kDa dimer of two identical disulfide-linked subunits existing in four molecular species; 121, 165, 189, and 206 amino acid residues long.
Immunogen
a synthetic peptide corresponding to amino acids from the N-terminus of human VEGF₁₆₅
Application
Immunoblotting (0.5 μg/ml, see comments and application references)
Paraffin Sections (5.0 μg/ml, trypsin or pressure cooker pre-treatment required)
Paraffin Sections (5.0 μg/ml, trypsin or pressure cooker pre-treatment required)
Physical form
In 50 mM sodium phosphate buffer, 0.2% gelatin, pH 7.5.
Analysis Note
Negative Control
Normal brain
Normal brain
Positive Control
Recombinant VEGF protein or fetal kidney
Recombinant VEGF protein or fetal kidney
Other Notes
For immunoblotting, include 1% BSA with the primary antibody. Antibody should be titrated for optimal results in individual systems.
Storage Class
10 - Combustible liquids
wgk
nwg
flash_point_f
Not applicable
flash_point_c
Not applicable
Regulatory Information
新产品
This item has
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Yvonne Arvidsson et al.
Endocrine-related cancer, 17(2), 303-316 (2010-01-15)
Tumour hypoxia is associated with increased metastatic potential and resistance to radiotherapy and chemotherapy. Ileal carcinoids are usually metastatic at the time of diagnosis and respond poorly to chemotherapy. The aim of this study was to investigate the extent of
VEGF/VPF: the angiogenesis factor found?
M Klagsbrun et al.
Current biology : CB, 3(10), 699-702 (1993-10-01)
L F Brown et al.
Kidney international, 42(6), 1457-1461 (1992-12-01)
Vascular permeability factor (VPF), also known as vascular endothelial growth factor (VEGF), is a potent microvascular permeability-enhancing mediator as well as a selective mitogen for vascular endothelium. In this study, in situ hybridization and immunohistochemistry co-localized VPF mRNA and protein